Cabergoline in Parkinson's Disease:Long-Term Follow-up
Neurol 43:2587-2590, Lera,G.,et al, 1993
Multictr Study of Cabergoline, A Long-Acting Dopamine Receptor Agonist, in PD Fluct Resp to Levodopa/Carbidopa
Neurol 43:1981-1984, Lieberman,A.,et al, 1993
Mitochondrial Involvement in Parkinson's Disease:The Controversy Continues
Neurol 43:2170-2172, DiMauro,S., 1993
Patent Foramen Ovale:Is Stroke Due to Paradoxical Embolism?
Stroke 24:31-34, Ranoux,D.,et al, 1993
A Prospective Study of Cerebral Ischemia in the Young, Analysis of Pathogenic Determinants
Stroke 24:362-367, Carolei,A.,et al, 1993
Classification of Subtype of Acute Ischemic Stroke, Definitions for Use in a Multicenter Clinical Trial
Stroke 24:35-41, Adams,H.P.,et al, 1993
An Analysis of Ischemic Stroke in an Urban Southern California Population
Arch Int Med 153:619-624, Rothrock,J.F.,et al, 1993
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 328:176-1831993., , 1993
The Clinical & Topographic Spectrum of Cerebellar Infarcts:A Clinical MR Imaging Correlation Study
Ann Neurol 33:451-456, Barth,A.,et al, 1993
Interphysician Agreement in Diagnosis of Subtypes of Acute Ischemic Stroke:Implic for Clin Trials
Neurol 43:1021-1027, Gordon,D.L.,et al, 1993
The Etiology of Posterior Circulation Infarcts:A Prospective Study Using MRI & MRA
Neurol 43:1528-1533, Bogousslavsky,J.,et al, 1993
Functional Integration of Cortical Grafts Placed in Brain Infarcts of Rats
Ann Neurol 34:362-368, Grabowski,M.,et al, 1993
Transplants for Stroke Patients
Ann Neurol 34:322-323, Sharp,F.R., 1993
Subcortical Dementia
BMJ 307:1-2, Dunne,F.J., 1993
The Prevalence of Metoclopramide-Induced Tardive Dyskinesia and Acute Extrapyramidal Movement Disorders
Arch Int Med 153:1469-1475, Ganzini,L.,et al, 1993
Thalamic Stimulation & Prox Tremor, A Specific Target in Nucleus Ventrointermedius Thalamik
Arch Neurol 50:498-500, Nguyen,J-P.&Degos,J-D., 1993
Progression After Chronic Manganese Exposure
Neurol 43:1479-1483, Huang,C.C.,et al, 1993
Comparisons of Therapeutic Effects of Levodopa
Levodopa & Selegiline, & Bromocriptine in Pts with Early, Mild Parkinson's, Parkinson's Res Grp in U, , BMJ 372,1993., 1993
Levodopa, Melanoma, and Parkinson's Disease
Neurol 43:674-677, Weiner,W.J.,et al, 1993
Comparison of Striatal 18F-dopa Uptake in Adult-Onset Dystonia-Parkinsonism, Parkinson's & Dopa-Responsive Dystonia
Neurol 43:1563-1568, Turjanski,N.,et al, 1993
Identical Twins with Similar Onset of Parkinson's Disease:A Case Report
Neurol 43:1159-1161, Pahwa,R.,et al, 1993
Parkinson's Disease:A Test of the Multifactorial Etiologic Hypothesis
Neurol 43:1173-1180, Semchuk,K.M.,et al, 1993
Environmental Causation of Parkinson's Disease
Arch Neurol 50:651-652, Rajput,A.H., 1993
The Nonenvironmental Basis for Rising Mortality from Parkinson's Disease
Arch Neurol 50:653-656, Riggs,J.E., 1993
Risk Factors for Parkinson's Disease
Neurol 43:1693-1697, 16411993., Hubble,J.P.,et al, 1993
Environmental Antecedents of Young-Onset Parkinson's Disease
Neurol 43:1150-1158, Butterfield,P.G.,et al, 1993
Olfactory Testing Differentiates Between Progressive Supranuclear Palsy & Idiopathic Parkinson's Dis
Neurol 43:962-965, Doty,R.L.,et al, 1993
Defecatory Function in Parkinson's Disease:Response to Apomorphine
Ann Neurol 33:490-493, Edwards,L.L.,et al, 1993
Multiple System Atrophy & Prog Supranuc Palsy, Dimin Striatal D2 Dopamine Receptor Act by SPECT
Arch Neurol 50:513-516, vanRoyen,E.,et al, 1993
Faithful Fashion:Survival Status of the Brain Transplant Cure for Parkinsonism
Neurol 43:644-649, Landau,W.M., 1993
Practice Parameters:Initial Therapy of Parkinson's Disease
Report of the Quality Standards Subcommittee of AAN, Neurol 43:1296-12971993., , 1993
Clinical Experience with Controlled-Release Carbidopa/Levodopa in Parkinson's Disease
Neurol 43:677-681, Pahwa,R.,et al, 1993
Movement Disorders with Cerebral Toxoplasmosis and AIDS
Movement Disorders 8:107-112, Nath,A.,et al, 1993
Neurosurgical Horizons in Parkinson's Disease
Neurol 43:1-7, Goetz,C.G.,et al, 1993
A Clinicopathologic Study of 100 Cases of Parkinson's Disease
Arch Neurol 50:140-148, Hughes,A.J.,et al, 1993
Increase of Parkinson Disability after Fluoxetine Medication
Neurol 43:211-213, Steur,E.N.H.J., 1993
Prognostic Significance of the Onset Mode in Parkinsonism
Neurol 43:829-830, Rajput,A.H.,et al, 1993
PET Imaging of the Dopamine Transporter with 11C-WIN 35, 428 Reveals Marked Declines in Mild Parkinson's Disease
Ann Neurol 34:423-431, Frost,J.J.,et al, 1993
Levodopa Improves Spatial Contrast Sensitivity in Parkinson's Disease
Arch Neurol 50:721-724, Hutton,J.T.,et al, 1993
T2 Relaxation Time in Patients with Parkinson's Disease
Neurol 43:697-700, Antonini,A.,et al, 1993
The Spectrum of Levodopa-Related Fluctuations in Parkinson's Disease
Neurol 43:1459-1464, Riley,D.E.&Lang,A.E., 1993
Blood Levodopa Levels and Unified Parkinson's Disease Rating Scale Function:With and Without Exercise
Neurol 43:1040-1042, Goetz,C.G.,et al, 1993
Contrast Agent Overdose Causing Brain Retention of Contrast, Seizures, and Parkinsonism
Neurol 43:836-838, May,E.F.,et al, 1993
Treatment of Parkinson's Disease
NEJM 329:1021-1027, Calne,D.B., 1993
Low Body Weight in Parkinson's Disease
S Med J 85:351-354, Jankovic,J.,et al, 1992
Suicide and Patients with Neurologic Diseases, Methodologic Problems
Arch Neurol 49:1296-1303, Stenager,E.N.&Stenager,E., 1992
Movement Disorders in Astrocytomas of the Basal Ganglia and the Thalamus
JNNP 55:1162-1167, Krauss,J.K.,et al, 1992
The Effect of Exercise on Levodopa Absorption
Neurol 42:2042-2045, Carter,J.H.,et al, 1992
Apomorphine Test for Dopaminergic Response in Pts with Previously Untreated Parkinson's
Arch Neurol 49:1131-1134, Gasser,T.,et al, 1992
Parkinson's Disease in Twins Studied with 18 F-Dopa and Positron Emission tomography
Neurol 42:1894-1900, Burn,D.J.,et al, 1992